435 related articles for article (PubMed ID: 25393730)
1. Mammalian target of rapamycin complex 2 signaling pathway regulates transient receptor potential cation channel 6 in podocytes.
Ding F; Zhang X; Li X; Zhang Y; Li B; Ding J
PLoS One; 2014; 9(11):e112972. PubMed ID: 25393730
[TBL] [Abstract][Full Text] [Related]
2. The mTORC2/Akt/NFκB Pathway-Mediated Activation of TRPC6 Participates in Adriamycin-Induced Podocyte Apoptosis.
Zhang HT; Wang WW; Ren LH; Zhao XX; Wang ZH; Zhuang DL; Bai YN
Cell Physiol Biochem; 2016; 40(5):1079-1093. PubMed ID: 27960162
[TBL] [Abstract][Full Text] [Related]
3. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
4. VEGF regulates TRPC6 channels in podocytes.
Thilo F; Liu Y; Loddenkemper C; Schuelein R; Schmidt A; Yan Z; Zhu Z; Zakrzewicz A; Gollasch M; Tepel M
Nephrol Dial Transplant; 2012 Mar; 27(3):921-9. PubMed ID: 21868397
[TBL] [Abstract][Full Text] [Related]
5. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
7. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes.
Vollenbröker B; George B; Wolfgart M; Saleem MA; Pavenstädt H; Weide T
Am J Physiol Renal Physiol; 2009 Feb; 296(2):F418-26. PubMed ID: 19019920
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of TRPC6 Signal Pathway Alleviates Podocyte Injury Induced by TGF-β1.
Huang H; You Y; Lin X; Tang C; Gu X; Huang M; Qin Y; Tan J; Huang F
Cell Physiol Biochem; 2017; 41(1):163-172. PubMed ID: 28214865
[TBL] [Abstract][Full Text] [Related]
10. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
[TBL] [Abstract][Full Text] [Related]
11. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
[TBL] [Abstract][Full Text] [Related]
12. mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.
Eid S; Boutary S; Braych K; Sabra R; Massaad C; Hamdy A; Rashid A; Moodad S; Block K; Gorin Y; Abboud HE; Eid AA
Antioxid Redox Signal; 2016 Nov; 25(13):703-719. PubMed ID: 27393154
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
[TBL] [Abstract][Full Text] [Related]
14. KU0063794, a Dual mTORC1 and mTORC2 Inhibitor, Reduces Neural Tissue Damage and Locomotor Impairment After Spinal Cord Injury in Mice.
Cordaro M; Paterniti I; Siracusa R; Impellizzeri D; Esposito E; Cuzzocrea S
Mol Neurobiol; 2017 May; 54(4):2415-2427. PubMed ID: 26960330
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.
Nijenhuis T; Sloan AJ; Hoenderop JG; Flesche J; van Goor H; Kistler AD; Bakker M; Bindels RJ; de Boer RA; Möller CC; Hamming I; Navis G; Wetzels JF; Berden JH; Reiser J; Faul C; van der Vlag J
Am J Pathol; 2011 Oct; 179(4):1719-32. PubMed ID: 21839714
[TBL] [Abstract][Full Text] [Related]
17. Insulin Increases Expression of TRPC6 Channels in Podocytes by a Calcineurin-Dependent Pathway.
Xia S; Liu Y; Li X; Thilo F; Tepel M
Cell Physiol Biochem; 2016; 38(2):659-69. PubMed ID: 26849622
[TBL] [Abstract][Full Text] [Related]
18. Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca2+ and RhoA activation.
Jiang L; Ding J; Tsai H; Li L; Feng Q; Miao J; Fan Q
Exp Biol Med (Maywood); 2011 Feb; 236(2):184-93. PubMed ID: 21321315
[TBL] [Abstract][Full Text] [Related]
19. TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases.
Ilatovskaya DV; Staruschenko A
Am J Physiol Renal Physiol; 2015 Sep; 309(5):F393-7. PubMed ID: 26084930
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.
Wazir U; Newbold RF; Jiang WG; Sharma AK; Mokbel K
Oncol Rep; 2013 May; 29(5):1969-74. PubMed ID: 23503572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
